Prostate Health Index (phi) Profile LabCorp

The Access Hybritech PSA assay is indicated for the measurement of serum PSA in conjunction with digital rectal examination (DRE) as an aid in the detection of prostate cancer in men aged 50 year or older.¹ This test is further indicated for the serial measurement of PSA to aid in the prognosis and management of patients with prostate cancer.

The Access Hybritech free PSA assay is intended to be used with Hybritech (total) PSA to calculate the ratio of free PSA to total PSA expressed as a percentage (percent free PSA).² Percent free PSA as measured by the Hybritech assays is indicated for use as an aid in distinguishing prostate cancer from benign prostatic conditions, when used in conjunction with Hybritech (total) PSA for prostate cancer detection in men aged 50 years and older with total PSA between 4 and 10 ng/mL (using Beckman Hybritech calibration) with digital rectal examination findings that are not suspicious for cancer.

The Prostate Health Index (phi) as calculated using the Beckman Coulter Access Hybritech assays is indicated for use as an aid in distinguishing prostate cancer from benign prostatic conditions, for prostate cancer detection in men aged 50 years and older with total PSA ≥4.0 to ≤10.0 ng/mL, and with digital rectal examination findings that are not suspicious for cancer.³

Prostatic biopsy is required for diagnosis of cancer.